MBX Biosciences (MBX) Enterprise Value (2024 - 2026)

MBX Biosciences has reported Enterprise Value for 4 years, with the latest figure at -$440.0 million in Q1 2026.

• Quarterly Enterprise Value fell 82.73% year-over-year to -$440.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$440.0 million (down 82.73% YoY) and the FY2025 annual result came in at -$373.7 million, down 42.55% from the prior year.
• Enterprise Value slipped to -$440.0 million in Q1 2026 per MBX's latest filing, from -$373.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at $115.9 million in Q2 2024 and troughed at -$440.0 million in Q1 2026.
• A 4-year average of -$187.8 million and a median of -$240.8 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 859.06% in 2024, then plunged 41.37% in 2025.
• Over 4 years, Enterprise Value stood at -$44.2 million in 2023, then slumped by 493.43% to -$262.1 million in 2024, then tumbled by 42.55% to -$373.7 million in 2025, then retreated by 17.73% to -$440.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$440.0 million, -$373.7 million, and -$391.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.